MetaCap

Ultragenyx Pharmaceutical (RARE) vs Schrodinger (SDGR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Schrodinger (SDGR) has outperformed Ultragenyx Pharmaceutical (RARE) over the past year, gaining 39.2% versus a loss of 50.9%. Over five years, SDGR leads with a -42.0% price change compared with -78.5% for RARE. Schrodinger is the larger company by market cap ($1.72 billion vs $1.68 billion), about 1.0 times the size.

Schrodinger converts more of its revenue into profit, with a net margin of -40.4% versus -85.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

RARE-50.94%SDGR+39.22%
+111%+21%-70%
Nov 21, 20251 yearNov 20, 2026
RARE-79.22%SDGR-43.80%
+38%-25%-88%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

RARE versus SDGR key metrics
MetricRARESDGR
Share price$16.48$22.93
Market cap$1.68B$1.72B
1-day change-4.30%-12.95%
YTD return-28.35%+28.24%
1-year return-50.94%+39.22%
5-year return-78.45%-42.01%
Forward P/E11.50—
EPS (TTM)$-5.17$-0.79
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$673.00M$255.87M
Revenue growth (YoY)+20.18%+23.29%
Net income (latest FY)$-575.00M$-103.27M
Gross margin—55.74%
Operating margin-79.49%-65.23%
Net margin-85.44%-40.36%
52-week high$39.89$34.00
52-week low$12.73$10.95
Distance from 52-week high-58.69%-32.56%
Analyst consensusbuybuy
Avg. price target upside+50.49%+46.40%
Average volume4.69M2.08M
Shares outstanding101.92M65.91M
Employees1,371850
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SDGR has outperformed RARE by 90.2 percentage points over the past year.
  • Schrodinger is more profitable, keeping -40.4 cents of every revenue dollar as net income versus -85.4 cents for Ultragenyx Pharmaceutical.

About Ultragenyx Pharmaceutical

RARE stock →

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,371 employees

About Schrodinger

SDGR stock →

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery.

Health Care · Biotechnology: Pharmaceutical Preparations · 850 employees

RARE vs SDGR FAQ

Which is bigger, Ultragenyx Pharmaceutical or Schrodinger?

Schrodinger (SDGR) is larger, with a market capitalization of $1.72B compared with $1.68B for Ultragenyx Pharmaceutical (RARE).

Which stock has performed better over the past year, RARE or SDGR?

SDGR returned +39.22% over the past 12 months, compared with -50.94% for RARE (price return, excluding dividends). Past performance does not predict future results.

Are Ultragenyx Pharmaceutical and Schrodinger in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons